Observational study shows immunotherapy improves outcomes in brain metastases from NSCLC, suggesting less influence from baseline factors.
This real-world study suggests that immunotherapy may confer a survival advantage over chemotherapy in NSCLC patients with brain metastases, with efficacy less dependent on baseline factors such as age or performance status. Radiotherapy administered before ICIs appeared to be associated with favorable outcomes, although this observation remains hypothesis-generating given the study limitations.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: